SCHEMBL6173291

SCHEMBL6173291

COC(=O)C(CC1CCCCC1)c1ccc(-n2nnnc2C(F)(F)F)c(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SLC6A3 Q01959 8/20 0.39
▸ LDHA P00338 1/20 0.38
▸ LDHB P07195 1/20 0.38
▸ KCNH2 Q12809 2/20 0.37
▸ GCK P35557 1/20 0.36
▸ APP P05067 1/20 0.36
▸ PSEN1 P49768 1/20 0.36
▸ PSEN2 P49810 1/20 0.36
▸ APH1B Q8WW43 1/20 0.36
▸ NCSTN Q92542 1/20 0.36
▸ APH1A Q96BI3 1/20 0.36
▸ PSENEN Q9NZ42 1/20 0.36
▸ SMURF1 Q9HCE7 1/20 0.34
▸ TACR1 P25103 1/20 0.34
▸ MDM4 O15151 1/20 0.34
▸ MDM2 Q00987 1/20 0.34
▸ SLC6A2 P23975 1/20 0.34
▸ SLC6A4 P31645 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2651023 0.89 APP (0.43) KCNH2GCKAPPPSEN1PSEN2
SCHEMBL6175163 0.87 SLC6A3 (0.41) SLC6A3KCNH2GCKSMURF1MDM4
SCHEMBL2658681 0.86 SLC6A3 (0.40) SLC6A3KCNH2GCKMDM4MDM2
SCHEMBL6172188 0.81 FFAR2 (0.54) KCNH2GCK
SCHEMBL6172615 0.80 SMURF1 (0.37) LDHALDHBKCNH2GCKAPP
SCHEMBL6174517 0.77 KCNH2 (0.39) LDHALDHBKCNH2MDM4MDM2
SCHEMBL2657371 0.77 KCNH2 (0.38) KCNH2GCKAPPPSEN1PSEN2
SCHEMBL2648953 0.76 SLC6A3 (0.63) SLC6A3KCNH2GCKSLC6A2SLC6A4
SCHEMBL2646655 0.76 SLC6A3 (0.63) SLC6A3KCNH2GCKSLC6A2SLC6A4
SCHEMBL6174485 0.76 KCNH2 (0.39) KCNH2GCKAPPPSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1311504-B1 TETRAZOLYL-PHENYL ACETAMIDE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2005-06-15 — — EP disclosed
US-6441180-B1 TO INCREASE INSULIN SECRETION, WHICH MAKES THEM USEFUL FOR TREATING TYPE II DIABETES HOFFMANN-LA ROCHE INC. 2002-08-27 — — US disclosed
US-20020065275-A1 Tetrazolyl-phenyl actamide glucokinase activators SIDDURI ACHYUTHARAO (US) 2002-05-30 — — US disclosed
US-6388088-B1 ANTIDIABETIC AGENTS HOFFMAN-LA ROCHE INC. 2002-05-14 — — US disclosed
US-6369232-B1 ANTIDIABETIC AGENTS HOFFMANN-LA ROCHE INC. 2002-04-09 — — US disclosed
US-20020035267-A1 Tetrazolyl-phenyl acetamide glucokinase activators SIDDURI ACHYUTHARAO (US) 2002-03-21 — — US disclosed
US-20020035266-A1 Tetrazolyl-phenyl acetamide glucokinase activators SIDDURI ACHYUTHARAO (US) 2002-03-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035267-A1 Tetrazolyl-phenyl acetamide glucokinase activators GCKR, GCK, PCK1 SLC6A3 2710/4885LDHA 1347/4885LDHB 2549/4885
US-20020035266-A1 Tetrazolyl-phenyl acetamide glucokinase activators GCKR, GCK, PCK1 SLC6A3 2710/4885LDHA 1347/4885LDHB 2549/4885
US-20020065275-A1 Tetrazolyl-phenyl actamide glucokinase activators GCKR, GCK, PFKL SLC6A3 2465/4885LDHA 1702/4885LDHB 2420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback